AlphAIAlphAI — Financial news for AI agents
tipranks.comSEP 211 min read$BSX

Boston Scientific price target lowered to $65 from $85 at Oppenheimer

Oppenheimer analyst Suraj Kalia reduced the price target for Boston Scientific (BSX) to $65 from $85, maintaining an Outperform rating. The firm also lowered its FY26 and FY27 estimates, citing a cybersecurity breach and competitive pressures in LAAC/EP.

Original reporting
tipranks.com
Published Sep 21, 2026, 1:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Boston Scientific price target lowered to $65 from $85 at Oppenheimer — source image
Source · tipranks.com
Decision brief

The 30-second read

$BSXBearishMed
01

Why it matters

The breach and competitive pressures prompted Oppenheimer to lower its FY26 and FY27 forecasts, reflected in the price‑target cut.

02

Market read

Analyst downgrade may trigger short‑term sell pressure ahead of earnings.

03

What to watch

Potential upside from upcoming product launches and recovery from breach.

Relevance 7/10Novelty 6/10Timing: ahead of quarterly results

Background

Boston Scientific recently experienced an eight‑day cybersecurity breach affecting ~9% of revenue‑producing days.

Company-level read

Ticker impact

$BSXBearishMedium confidence
Context

Oppenheimer lowered Boston Scientific's price target to $65 from $85 ahead of its quarterly results.

Expected impact

Potential short‑term decline or increased volatility ahead of earnings.

Evidence & confidence

Target reduction reflects concerns over recent cyber‑security breach impact and competitive pressures.

Market effects

Sector

May weigh on med‑tech sector as peers assess cyber‑risk exposure.

Regional

Limited to US healthcare equities.

Global

Minimal global impact beyond Boston Scientific.

Counterpoint

What could challenge this read

Investors could view the cut as overreaction given long‑term growth prospects.

Key entities

  • Company
    Boston Scientific

    Medical device manufacturer (ticker BSX).

  • Analyst Firm
    Oppenheimer

    Equity research firm providing the price‑target revision.

Read at source← All news

Related articles

SEP 19
$TCOMMed

Trip.com, Boston Scientific, Lyft, WES, Magna Trending With Analysts - TipRanks.com

Analysts updated ratings for five stocks: Trip.com (TCOM) was upgraded to Buy with a $53.20 target, citing international growth. Boston Scientific (BSX) was downgraded to Hold with a $50 target due to market pressures. Lyft (LYFT) was downgraded to Hold with a $16 target over near-term concerns. Western Midstream (WES) was initiated as Buy with a $55 target, highlighting growth prospects. Magna (MGA) was downgraded to Hold with a $70 target due to macroeconomic risks.

tipranks.com3 min
SEP 18
$BSXLow

SPONGE Trial, Targeting GI Leak Treatment and New Growth

Boston Scientific (BSX) is launching a multicenter trial to evaluate the safety and effectiveness of its Eso-SPONGE device for treating upper GI leaks. The trial aims to assess the device's ability to close leak sites post-surgery, offering a less invasive alternative. The study is not yet recruiting, with updates indicating active planning. Positive results could support BSX's pipeline in minimally invasive GI solutions and potentially impact competitors.

tipranks.com2 min
SEP 13
$BSXHigh

Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance.

Boston Scientific (BSX) fell 2.3% after a cyberattack disrupted operations, leading to a guidance cut for Q3 and 2026. The attack caused shipping delays, not demand issues, and the company expects recovery. BSX faces competitive pressure in the electrophysiology market. Hedge fund holdings decreased slightly, with low short interest. The company's long-term outlook remains intact, but near-term visibility is weak.

yahoo.com2 min